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Study Objectives: To compare self-reported sleep quality, treatment compliance, and respiratory event index (REI) after 4 months of 
treatment with mandibular advancement device (MAD) or continuous positive airway pressure (CPAP) in mild and moderate obstructive 
sleep apnea (OSA). 
Materials and Methods: A total of 104 patients with mild or moderate OSA were randomly allocated to MAD or CPAP treatment and 
followed for 4 months. Data were collected through type 3 polygraphic sleep recordings, CPAP recordings, medical examination, and 
the Pittsburgh Sleep Quality Index (PSQI). Chi-square test, t-test, and Mann-Whitney U test were used to analyze compliance, PSQI 
global score and REI, respectively. Reliable change index (RCI) was used to evaluate change in PSQI global score. 
Results: Six patients were lost to follow-up. More patients were compliant with MAD treatment (79.5%) than CPAP treatment (38.9%) 
at follow-up (P<0.001). Both groups had improved PSQI global scores: MAD (8.0±3.1 to 5.7±2.5, P<0.001) and CPAP (7.7±3.5 to 
6.7±3.4, P=0.01). More patients had improved PSQI global score according to the RCI in the MAD group (38.6%) than in the CPAP 
group (16.7%) (P=0.01). Both treatments reduced REI (P<0.001), but CPAP (REI=1.1) more so than MAD (REI=7.9) (P<0.001). 
Conclusions: Both MAD and CPAP treatment improve self-reported sleep quality in patients with mild and moderate OSA. More 
patients comply with MAD treatment, which improves sleep quality in more patients than does CPAP, despite REI being lower in the 
CPAP group. With respect to sleep quality, MAD treatment should be considered a better treatment option than CPAP in mild and 
moderate OSA. 
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Obstructive sleep apnea (OSA) is characterized by 
repeated collapse of the soft tissues in the upper airway and 
leads to sleep fragmentation and reduced sleep quality.1-3 
The severity of OSA is measured by the apnea-hypopnea 
index (AHI) and is graded as mild (AHI 5-14.9 events/h), 
moderate (AHI 15-29.9 events/h) and severe (AHI >30 
events/h).4 When OSA is diagnosed through unattended 
sleep apnea testing the AHI is substituted by the respiratory 
event index (REI).5 Continuous positive airway pressure 
(CPAP) reduces respiratory events by eliminating the 
negative respiratory pressure that collapses the upper 
airways.6 Despite challenges regarding patient adherence, 
CPAP is currently regarded as the gold standard for 
treatment of all patients with OSA,7 whereas exercise 
training and weight loss are recommended as adjunct 
treatments for all patients with OSA who are overweight.8,9 
In addition, surgical interventions are indicated in selected 
groups of patients with OSA.10-12 For patients with primary 
snoring or mild OSA or those who are unable or unwilling 
to use CPAP, a mandibular advancement device (MAD) is 
regarded as an adequate alternative.7,13,14 MADs relocate 
and fixate the mandible in a protruded position when used, 
thus increasing the retropalatal and retroglossal volume and 
thereby reducing the collapsibility of the upper airways.15,16 
Although CPAP treatment is known to be superior to MAD 
treatment in regard to respiratory event reduction,7,10,17 
several studies have shown patients adhering better to 
MAD and preferring MAD over CPAP when given the 
choice.18-21 Both CPAP and MAD treatments are associated 
with only mild and transient adverse effects such as 
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pressure in the face, mild pain in teeth and jaw, or changes 
in salivation,10,16,19,22 suggesting that factors other than 
adverse effects from CPAP and MAD have an effect on the 
patient’s preferences and motivation in OSA treatment.15,20 
The patient’s perceived sleep quality while using CPAP or 
MAD might be one such factor, but self-reported sleep 
quality during OSA treatment is not extensively 
studied.17,23 Contrary to polysomnographic analysis of 
sleep quality, which shows sleep efficacy and changes in 
sleep stages during OSA treatment,24,25 self-reported sleep 
quality shows how the patient experiences the effect of 
OSA treatment on sleep quality. It is currently not clear 
which OSA treatment is better at improving self-reported 
sleep quality, or how much improvement could be expected 
in patients with mild and moderate OSA.2 To our 
knowledge, no randomized controlled trial has previously 
measured and compared the effect of CPAP and MAD 
treatment on self-reported sleep quality in patients with 




In this study we aimed to compare self-reported sleep 
quality after initial phase (4 months) of MAD or CPAP 
treatment in mild and moderate OSA. Secondary aims were 
to compare treatment compliance and change in REI from 
baseline to follow-up. 
 
MATERIALS AND METHODS 
 
Study Design  
 
This study was a two-centered parallel arm 
randomized controlled clinical trial, with 50/50 allocation 
ratio. Blinding of the patients and clinical personnel was 
not feasible because of the nature of the OSA treatment. 
 
Ethical Approval  
 
The trial was approved by the Norwegian Regional 
Committee for Medical and Health Research Ethics, REC 
Central (registration #2014/956) and was registered in 




Two researchers (LMB and TKSA) calibrated all 
personnel involved in the patient treatment and data 
collection according to the trial protocol. The protocol 
checklists complied with the later updated American 
Academy of Sleep Medicine practice guidelines for 
diagnostic testing for OSA.26 
 
Recruitment and Randomization 
 
All patients in the trial were referred from primary 
health care to the ear-nose-throat departments at the 
University hospital of Northern Norway (UNN) in Tromsø, 
St. Olavs University Hospital (St. Olavs), and Aleris 
Hospital in Trondheim, Norway. All patients were screened 
for OSA by ambulatory type 3 sleep recording devices 
(Embletta® or Nox T3™, ResMed Norway AS) at home or 
at a hotel. Respiratory events were defined as >90% 
reduction in respiratory flow or >50% reduction in 
respiratory flow combined with ≥3% oxygen desaturation 
from baseline respectively. The sleep recordings were 
manually analyzed by sleep technicians at the three 
hospitals before otorhinolaryngologists at UNN and St. 
Olavs Hospitals performed a medical examination of the 
patients. All patients meeting the inclusion criteria were 
invited to participate in the study by the 
otorhinolaryngologist. 
Inclusion criteria were age 20 to 75 years, REI 
between 10.0 and 29.9, and ability to protrude the mandible 
at least 5 mm. Exclusion criteria were pregnancy, drug 
abuse, daily use of sedative medication, preexisting severe 
psychiatric disorders, or somatic health issues such as 
temporomandibular dysfunction that prevented the use of 
CPAP or MAD.  
After providing informed written consent to 
participate, the patients were randomized to treatment with 
either CPAP or MAD. The patients drew lots from a 
masked envelope for random allocation. Block-
randomization with 30 lots per block at each of the two 
study sites was used to prevent skewed distribution 
between CPAP and MAD groups across seasons and study 
sites. 
 
Treatment Protocol and Questionnaires 
 
The treatment protocol was based on the 
recommendations from the Standards of Practice 
Committee and the Board of Directors of the American 
Academy of Sleep Medicine.27 Patients allocated to the 
CPAP group met a sleep technician on 2 consecutive days 
for adaptation and adjustment of the CPAP-machine 
(Resmed®, San Diego, California, USA). A facemask or 
nose mask was used depending on the patient’s needs and 
preference. The patients had the opportunity to see the 
sleep technicians for adjustments of the CPAP machine 
when necessary.  
Patients allocated to the MAD group met a dentist and 
dental hygienist or dental nurse for impression of the 
dentition, bite registration using the George gauge™ 
(Scheu-dental GmbH, Iserlohn, Germany) and ordering the 
MAD (Respire Medical, New York, New York, USA and 
SomnoDent®, Sydney, New South Wales, Australia). At 
the second visit to the dental team the MAD was set 
between 60% and 65% of maximum protrusion of the 
mandible. Necessary changes to the MAD based on patient 
feedback were made after 2 to 3 weeks. The patients had 
the opportunity to see the dental team for further 
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adjustments of the MAD when necessary. 
At the medical examination prior to treatment, all 
patients completed the Pittsburgh Sleep Quality Index 
(PSQI) a 19-item validated questionnaire measuring self-
perceived sleep quality during the previous month. PSQI 
assess 7 aspects of sleep quality: subjective sleep quality, 
sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medicine, and daytime 
dysfunction, which are transformed into a global score. The 
PSQI global score has a possible range of 0-21 points, with 
≤5 points representing good sleep quality.28 
To evaluate whether the change in PSQI for each 
individual patient was clinically and statistically 
significant, the reliable change index (RCI) as described by 
Jacobson and Truax29 was used. The RCI was calculated by 
using the standard deviation from pretreatment PSQI 
global score and a test-retest reliability at 0.85.28 An RCI 
value <-1.96 indicate that the patient’s reduction in PSQI 
global score is statistically significant on a 5% level, and 
thus not likely to occur due to expected test-retest 
variations. The patients also completed a 12-item 
questionnaire assessing general health, socioeconomic 
status, and smoking and alcohol habits. 
At follow-up after approximately 4 months, all 
patients completed the PSQI questionnaire and a 
questionnaire covering self-reported compliance to both 
the CPAP and MAD group. Recordings of usage and REI 
were downloaded from the CPAP machine, whereas 
patients using MAD recorded REI through a new 
polygraphic sleep recording while using the MAD. Sleep 
technicians at UNN and St. Olavs hospitals analyzed both 
CPAP recordings and the new polygraphic sleep 
recordings. Patients were regarded as compliant with 
treatment if they reported using the CPAP or MAD more 




Both intention-to-treat (ITT) analyses (all included 
patients) and per-protocol (PP) analyses (patients 
compliant with treatment) are presented for the primary 
aim and compliance.30 REI was analyzed according to ITT 
only. At follow-up, the MAD and CPAP groups were 
compared using the t-test (PSQI), Mann-Whitney U test 
(REI), and Pearson chi-square test (compliance with 
treatment). Change within treatment groups in PSQI global 
score and REI from baseline to follow-up was analyzed 
using paired-samples t-test and Wilcoxon signed-rank test, 
respectively. Missing entries in PSQI were replaced by 
multiple imputations as recommended by CONSORT 
2010.31,32 The number of patients with RCI<-1.96 in each 
treatment group was compared using Pearson chi-square 
test. All statistical analyses were done using SPSS 25 
statistical software package (IBM Corp, Armonk, New 
York, USA) and a two-sided value of P<0.05 was 
considered statistically significant. 
Sample Size 
 
Based on an expected 15% difference in PSQI global 
score between treatment groups at follow-up and a 
common standard deviation within groups at 25%, a 
sample size of 45 patients in each treatment group was 
needed to detect differences in a t-test between the groups 
at a 5% significance level (two-tailed analysis) and 
reaching 80% power. Assuming a 10% dropout rate, a 




Participant Flow, Dropouts, and Treatment 
Compliance 
 
Patients were recruited to the study between October 
2014 and February 2018. A total of 104 patients satisfied 
the inclusion criteria and signed a written consent to 
participate in the trial. Forty-nine patients were allocated to 
MAD treatment and 55 were allocated to CPAP treatment. 
The flow of patients in the study is illustrated in Figure 1. 
Thirty-eight patients with a MAD and 45 patients using 
CPAP had no missing data throughout the trial. After 
replacing missing PSQI entries through imputations, 44 
patients using a MAD and 54 patients using CPAP were 
included in the PSQI analyses at 4 months. Median time 
from treatment start to follow-up was 4 months, range 2 to 
8 months. Follow-up was ended in January 2019. 
The 11 patients ceasing treatment before follow-up 
were demographically similar to the remaining study 
population at baseline and were evenly distributed between 
mild and moderate OSA. Information on compliance was 
available for 98 patients. The chi-square test showed more 
patients being compliant with MAD treatment (79.5%) 
than CPAP treatment (38.9%) at follow-up (P<0.001). 
 
Baseline Data and Outcome Variables 
 
Demographic patient data at baseline are presented in 
Table 1 and were uniformly distributed between the 
treatment groups. The distribution was similar in the ITT 
and PP analysis (supplementary Table S 1). 
 
PSQI Global Score 
 
From baseline to follow-up, mean PSQI global score 
was reduced in both treatment groups in the ITT analysis: 
MAD group from 8.0±3.1 to 5.7±2.5, P<0.001 and CPAP 
group from 7.7±3.5 to 6.7±3.4, P=0.01. PP analysis 
including only patients with treatment compliance also 
showed reduced PSQI global score in both treatment 
groups: MAD group from 8.1±3.1 to 5.3±2.5, P<0.001 and 
CPAP group from 7.1±3.5 to 5.8±3.3, P=0.02. The PSQI 
global score did not differ between the treatment groups at 
follow-up (Table 2). 
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MAD: Mandibular Advancement Device 




Table 1. Demographic patient data at baseline, all included patients 
Baseline variables MAD (n=49) CPAP (n=55) 
Age at inclusion a 49.6 (9.0) 53.3 (10.2) 










































College or university 







≤ Once per week 














aMean (standard deviation), all other variables: n (%). 
BMI, body mass index (kg/m2); CPAP, continuous positive airway  
pressure; MAD, mandibular advancement device; OSA, obstructive  
sleep apnea. (kg/m2). 
 
Patients willing to participate and eligible to the trial (n = 104) 
 
Allocated to 
MAD (n = 49) 
Allocated to 
CPAP (n = 55) 
PSQI follow-up MAD (n = 44) PSQI follow-up CPAP (n = 54) 
Quit treatment (n = 6) 
 
Quit treatment (n = 5) 
 
Lost to follow-up (n = 5) Lost to follow-up (n = 1) 
Sleep data MAD follow-up (n = 38) Sleep data CPAP follow-up (n = 49) 
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Table 2. PSQI and REI at baseline and follow-up. 
 





































P indicates t-test/Mann-Whitney U test between MAD and CPAP group at follow-up. 
Mean (standard deviation). median (interquartile range).  
ITT, intention to treat; PP, per protocol; PSQI, Pittsburgh Sleep Quality Index (global 
score); REI, respiratory event index (events/h).  
aStatistically significant change from baseline within treatment group (P<0.05). 
bMAD n=35 at follow-up, CPAP n=21 at follow-up. 
cMAD n=38 at follow-up, CPAP n=49 at follow-up. 
 
Reliable Change in PSQI Global Score 
 
According to the RCI, significantly more patients in 
the MAD group than in the CPAP group reported 
improvement in sleep quality, that is, having RCI <-1.96 
for the change in PSQI global score from baseline to 




Table 3. Number of patients with significantly improved 
PSQI global score (RCI<-1.96). 
 Significantly improved 
PSQI global score (RCI<-1.96) 
 MAD CPAP P 










ITT, intention to treat; PP, per protocol; P, Pearson chi-
square test; PSQI, Pittsburgh Sleep Quality Index (global 
score); RCI, reliable change index. 
 
 
Respiratory Event Index 
 
Both treatment groups had a reduction in median REI 
from baseline to follow-up: MAD group from 16.3 (12.4 – 
23.0) to 7.9 (6.0 – 13.7), P<0.001 and CPAP group from 
18.1 (15.3 – 24.6) to 1.1 (0.6 – 1.6), P<0.001 (Table 2). The 







In this randomized controlled clinical trial we 
compared the effect of CPAP and MAD treatment on self-
reported sleep quality in patients with mild and moderate 
OSA. After 4 months of treatment, self-reported sleep 
quality was improved in both treatment groups. Although 
PSQI global score at follow-up was similar between the 
treatment groups, the difference in the number of patients 
reporting a reliable improvement in PSQI global score was 
significant. Patients reporting an improved PSQI global 
score according to the RCI are assumed to also have 
clinically improved sleep quality from baseline to follow-
up.33 This means that 38.6% of patients using a MAD and 
16.7% of patients using CPAP in our trial experienced an 
improvement in perceived sleep quality, even though the 
absolute change in PSQI global score seem modest. By 
using the RCI, we counteract the effect from possible 
outliers in PSQI change, thereby limiting the possible 
influence from factors not related to OSA on the PSQI 
change at group level. 
It is reasonable to believe that effective treatment of 
OSA should improve sleep quality.24,34 Both treatment 
groups in this trial significantly reduced the REI, indicating 
that both MAD and CPAP have a considerable positive 
effect on mild and moderate OSA. In the CPAP group the 
REI was reduced to 1.1, well below the limit for having 
OSA.4 The MAD group had on average a residual REI at 
7.9, which is unsurprising as the MAD by increasing the 
volume of the upper airway merely reduce the negative 
respiratory pressure, not fully eliminate the collapsibility 
of the upper airways.16 Although reducing the REI by more 
than 50%, the residual REI may be contributing to PSQI 
global score remaining above 5.0 in the MAD group at 
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follow-up. However, CPAP treatment also did not reduce 
PSQI global score below 5.0, showing that the PSQI global 
score is dependent on more factors than REI.2,23 The 
limited reduction of PSQI global score in the CPAP group 
may be due to low CPAP compliance in the ITT analysis. 
However, the PP analysis showed that when only including 
patients who used the MAD or CPAP more than 4 hours, 
more than 50% of nights, more patients using MAD than 
using CPAP report improved sleep quality according to the 
RCI (Table 3). This trend was even more pronounced when 
using 4 hours and 70% of nights as the lower limit for 
compliance (P=0.02, table not shown), indicating that 
MAD treatment, despite having higher residual REI, is 
better than CPAP treatment at improving self-reported 
sleep quality. Previous studies have indicated that MAD is 
perceived as a less invasive treatment alternative and is 
preferred over CPAP treatment in most studies where 
patients have been treated with both appliances.8,15,18 This 
is not only in line with our findings regarding treatment 
compliance, but also indicates why MAD seems to be 
better at improving sleep quality, given that CPAP 
treatment may be uncomfortable and thus impair sleep 
quality while simultaneously lowering REI.35,36 
This study deviates from the more common cutoff 
level for treatment compliance being >4 hours, >70% of 
nights21 because only 33 MAD patients (76.7%) and 17 
CPAP patients (31.5%) would be regarded as compliant 
with treatment, further reducing statistical power in the PP 
analyses. Regardless of compliance cutoff level, treatment 
compliance in this study was better with MAD than with 
CPAP, a finding that also was found in a recent meta-
analysis.37 Furthermore, the poor compliance with CPAP 
treatment in this trial is in line with another meta-analysis 
where CPAP compliance became worse with reduced OSA 
severity.21 Fortunately, the risk of serious cardiovascular 
events and death seems to be small in mild and moderate 
OSA compared to severe OSA.38-40 This finding, and the 
debated role of respiratory events as a predictor for 
cardiovascular events and early death, suggests that good 
compliance with treatment may be more important than 
optimal reduction of respiratory events, as long as the 
residual REI is within preferably mild and perhaps 
moderate OSA.41,42 Achieving patient- perceived benefits 
of OSA treatment such as improved sleep quality should 
therefore be considered part of the treatment goal, 
especially in mild and moderate OSA, where factors other 
than disease severity seem to be important for motivation 
and compliance to treatment.21,35,43 To bypass concerns 
related to treatment compliance, mandibular advancement 
surgery may be considered in patients in whom REI is 
effectively reduced and sleep quality is improved with 
MAD treatment. Surgical mandibular advancement 
reduces REI through mechanisms similar to MAD 
treatment, but the invasive nature of such a surgical 
procedure makes it more suited for patients having severe 
OSA and should not be considered in patients where there 
are high risks of postsurgical malocclusion or poor facial 
esthetics.12,44 
The randomization procedure in this trial was 
successful; thus, any first-night effects in the polygraphic 
sleep recordings26,45 or placebo effects on sleep quality in 
this initial phase of treatment should be equal in the two 
treatment groups because of the study design.46 However, 
there was a risk of recruitment bias because the study was 
unblinded and some patients could be familiar with either 
MAD or CPAP treatment before agreeing to participate in 
the trial. To minimize this risk, only patients who had not 
in any way been treated for OSA previously were invited 
to the trial. Patients in this trial deviated from the 
Norwegian general population by having higher average 
body mass index and worse self-reported general health at 
baseline.47,48 
One major limitation of this study is the uncertainty of 
using self-reported compliance. Objectively measured 
compliance was available for the CPAP group only, which 
showed minor discrepancies between self-reported and 
objectively measured compliance for 6 patients. There are 
no reasons to believe that patients in the MAD group are 
less honest than those in the CPAP group when reporting 
on their use of the appliance. Moreover, very good 
agreement between subjective and objective measured 
compliance in MAD patients was found in previous 
studies.49 PP analyses using objectively measured 
compliance for the CPAP group are presented in the 
supplementary Table S 2 and supplementary Table S3. 
Imputed data were used in the primary analysis as 
recommended by the CONSORT 2010 statement to avoid 
compromising the methodologic strengths of the 
randomization.31 Results from analysis only including 
patients with no imputed data are presented in the 
supplementary Table S 4 and supplementary Table S 5. 
Fisher exact test showed that the 6 patients without any 
information on compliance were similar to the rest of the 
patients at baseline (data not shown). Furthermore, the 5 
patients who were lost to follow-up in the MAD group 
were missing at random. The missing patients in this trial 
are therefore unlikely to create any bias at follow-up. 
Although sleep data on follow-up was available in fewer 
patients in the MAD group (77.6%) than in the CPAP group 
(89.1%), this difference was not statistically significant 




In summary, both MAD and CPAP treatment improve 
self-reported sleep quality in patients with mild and 
moderate OSA. When using the CPAP device, the CPAP 
group achieved a lower REI than the MAD group. 
Nevertheless, significantly more patients in the MAD 
group comply with the treatment and report a significant 
improvement in PSQI global score compared to the CPAP 
group. Regarding sleep quality, MAD should be considered 
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AHI – apnea-hypopnea index 
CPAP – continuous positive airway pressure 
ITT – intention to treat 
MAD – mandibular advancement device 
OSA – obstructive sleep apnea 
PP – per protocol 
PSQI – Pittsburgh Sleep Quality Index 
RCI – reliable change index 
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Table S 1. Distribution of patient characteristics in intention-to-treat and per protocol analysis 








Age at inclusiona 49.6 (9.0) 53.3 (10.2) 49.9 (9.2) 55.1 (10.9) 








































































College or university 













≤ Once per week 


























BMI, body mass index (kg/m2); CPAP, continuous positive airway pressure; ITT, intention to treat; MAD,  
mandibular advancement device; OSA, obstructive sleep apnea; PP, per protocol.  
aMean (standard deviation), all other variables: n (%). 
 
Table S 2. PSQI and REI at baseline and follow-up (Objectively measured CPAP 
compliance and self-reported MAD compliance, >4 hours, >50% of nights). 



















CPAP, continuous positive airway pressure; MAD, mandibular advancement device; 
PP, per protocol; PSQI, Pittsburgh Sleep Quality Index (global score). P indicates t-test 
between MAD and CPAP group at follow-up. 
 
aStatistically significant change from baseline within treatment group (P<0.05). 
 
bMAD n=35 at follow-up, CPAP n=17 at follow-up. 
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Table S 3. Number of patients with significantly improved PSQI global score (RCI<-
1.96) (objectively measured CPAP compliance and self-reported MAD compliance, >4 
hours, >50% of nights). 
 
 Improved PSQI global score 
 MAD CPAP P 











CPAP, continuous positive airway pressure; ITT, intention to treat; MAD, mandibular 
advancement device; PP, per protocol; PSQI, Pittsburgh Sleep Quality Index (global 
score). P indicates Pearson chi-square test. 
 






CPAP, continuous positive airway pressure; ITT, intention to treat; MAD, mandibular 
advancement device; PP, per protocol; PSQI, Pittsburgh Sleep Quality Index (global 
score); REI, respiratory event index (events/h). P indicates Difference between MAD 
and CPAP group at follow-up. 
 
aStatistically significant change from baseline within treatment group (P<0.05). 
 
bMAD n=33, CPAP n=16. 
 
cMAD n=36 at follow-up, CPAP n=43 at follow-up. 
 
Table S 5. Number of patients with significantly improved PSQI global score 
(RCI<1.96) (no patients with imputed data). 
 Statistically significant 
improvement 
 MAD CPAP P 










CPAP, continuous positive airway pressure; ITT, intention to treat; MAD, mandibular 
advancement device; PP, per protocol; PSQI, Pittsburgh Sleep Quality Index (global 
score). P indicates Pearson chi-square test. 
  
 




























REIc  17.1 
(12.5-22.8) 
17.5 
(14.6-23.0) 
7.9 a 
(6.0-13.2) 
1.1a 
(0.6-1.6) 
<.001 
